272 related articles for article (PubMed ID: 30196727)
1. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.
Soto-Perez-De-Celis E; Loh KP; Baldini C; Battisti NML; Chavarri-Guerra Y; De Glas NA; Hsu T; Hurria A
Expert Opin Investig Drugs; 2018 Oct; 27(10):787-801. PubMed ID: 30196727
[TBL] [Abstract][Full Text] [Related]
2. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
5. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.
Yu Q; Zhu Z; Liu Y; Zhang J; Li K
PLoS One; 2015; 10(5):e0127404. PubMed ID: 25993646
[TBL] [Abstract][Full Text] [Related]
8. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
9. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
Aapro M; Cardoso F; Curigliano G; Eniu A; Gligorov J; Harbeck N; Mueller A; Pagani O; Paluch-Shimon S; Senkus E; Thürlimann B; Zaman K
Breast; 2022 Dec; 66():145-156. PubMed ID: 36279803
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
Kotecki N; Gombos A; Awada A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
[No Abstract] [Full Text] [Related]
11. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
12. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
13. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab in gastrointestinal cancer.
Oh DY; Bang YJ
Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
[TBL] [Abstract][Full Text] [Related]
17. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
18. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
Janjigian YY; Braghiroli MI
Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
20. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
